Journal
EXPERT OPINION ON DRUG SAFETY
Volume 12, Issue 4, Pages 545-557Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/14740338.2013.793671
Keywords
DPP-4 inhibitor; gliptin; glucagon-like peptide-1; pancreatitis; pharmacovigilance; type 2 diabetes mellitus
Categories
Funding
- AstraZeneca/BMS
- Boehringer Ingelheim
- Eli Lilly
- GlaxoSmithKline
- Merck Sharp Dohme
- Novartis
- NovoNordisk
- Sanofi-Aventis
Ask authors/readers for more resources
Introduction: Dipeptidyl peptidase-4 (DPP-4) inhibitors (gliptins) play an increasing role in the management of type 2 diabetes. Such incretin-based therapies offer some advantages over other glucose-lowering agents, but might be associated with an increased risk of acute pancreatitis. Areas covered: An extensive literature search was performed to analyze clinical cases of acute pancreatitis reported in the literature or to the Food and Drug Administration (FDA), in randomized clinical trials, and in observational studies with five DPP-4 inhibitors: sitagliptin, vildagliptin, saxagliptin, alogliptin, and linagliptin. Expert opinion: An increased risk of pancreatitis has been reported in diabetic versus nondiabetic patients. Several anecdotal clinical cases of pancreatitis have been reported with sitagliptin and vildagliptin and an increased relative risk reported to the FDA with sitagliptin versus other comparators, but reporting bias cannot be excluded. In rather short-term clinical trials with well-selected diabetic patients, no increased risk of acute pancreatitis has been observed with any of the five commercialized DPP-4 inhibitors: sitagliptin, vildagliptin, saxagliptin, alogliptin, and linagliptin. Similarly, real-life cohort studies showed no increased incidence of pancreatitis with gliptins compared with other glucose-lowering agents, a finding recently challenged by a case-control study. These results must be confirmed in postmarketing surveillance programs and in ongoing large prospective trials with cardiovascular outcomes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available